S. Korean biotech snags financing with help from U.S. venture group

South Korea-based CrystalGenomics has reeled in $2.6 million in funding from the Korea Seoul Life Science Fund (KSLSF) to advance its R&D programs in pain and infectious diseases, including an NSAID for patients with osteoarthritis, according to a company release. The company noted U.S. venture firm Oxford Bioscience Partners and Hanwha Venture Capital's roles as general partners in its backer KSLSF. The government of South Korea was a major contributor to Boston-based Oxford's sixth fund announced in early 2011. Release

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.